EXEL - Exelixis shareholder Farallon to nominate three to biotech's board
2023-03-27 17:50:01 ET
- Farallon Capital Management, which has a 7.2% stake in Exelixis ( NASDAQ: EXEL ), said that it intends to nominate three individuals to the biotech's board.
- They are Tomas Heyman, David Johnson and Robert Oliver, Jr.
- In an SEC filing , Farallon said it notified Exelixis ( EXEL ) of its plans on March 23.
- A week ago, Farallon said Exelixis ( EXEL ) was undervalued and needed a board refresh .
For further details see:
Exelixis shareholder Farallon to nominate three to biotech's board